

The Board:

1. Notes the Secretariat's review of the items on the 2014 – 2016 allocation period's unfunded quality demand ("UQD") register, as described GF/B36/ERO4;
2. Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Bangladesh TB, (ii) Central African Republic TB/HIV, (iii) Myanmar TB, (iv) Philippines TB, and (v) Viet Nam TB, as listed in Table 4 of Section IV to GF/B36/ERO4, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;
3. Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

01 Table 4: Secretariat's Recommendation on Financing Unfunded Quality Demand

N	Applicant	Disease Component	Grant Name	Currency	Previously Approved Grant Budget	Revised Budget for Board Approval	Source of Recommended Additional Funding	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Bangladesh	TB	BGD-T-BRAC	US\$	44,336,544	46,386,647 ¹	Portfolio Optimization and Private Sector Contribution	8,450,796	0	35,885,748	1,859,567	3,999,999	19,210,000
			BGD-T-NTP		36,367,177	38,605,858 ²		6,037,096	0	23,923,904	2,140,432		
2	Central African Republic	TB/HIV	CAF-C-IFRC	€	16,050,093	20,375,214	Portfolio Optimization	5,115,291	0	10,934,802	4,325,121	4,325,121	0
3	Philippines	TB	PHL-T-PBSP	US\$	115,562,488 ³	120,853,998	Portfolio Optimization	77,536,167	0	38,026,321	5,291,510	5,291,510	0
4	Viet Nam	TB	VNM-T-NTP	US\$	39,439,638	42,757,599 ⁴	Portfolio Optimization	16,315,143	0	23,124,495	3,000,000	3,000,000	36,848,472
5	Myanmar	TB	MYN-T-SCF	US\$	See Table 3.	Portfolio Optimization	See Table 3.				5,110,483 ⁵	5,110,483	See Table 3.
			MYN-T-UNOPS										

¹ Reflects the revised Board approved budget of US\$44,336,544 incorporating reinvestment of savings (GF/B34/ER05), previously signed special initiative funding of US\$190,536, and the additional incremental funding amount of US\$1,859,567.

² Reflects the revised Board approved budget of US\$36,367,177 incorporating reinvestment of savings (GF/B34/ER05), previously signed special initiative funding of US\$98,249, and the additional incremental funding amount of US\$2,140,432.

³ Reflects program budget amount of US\$115,562,488 whereas GF/B35/ER11 made reference to the signed grant amount of US\$108,440,114

⁴ Reflects the original Board Approved budget of US\$39,439,638, the revised approved budget amount of US\$39,757,599 incorporating the previously signed special initiative funding of US\$323,143, and the additional incremental funding amount of US\$3,000,000.

⁵ See rows 3 and 4 of Table 3. Additional funding recommended to finance UQD for Myanmar TB of US\$5,110,483 has been integrated into the total program budgets for MYN-T-SCF and MYN-T-UNOPS as part of the overall 2017 Myanmar TB/HIV Early Applicant funding request.